|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jordan CT, Guzman ML and Noble M: Cancer
stem cells. N Engl J Med. 355:1253–1261. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bonnet D and Dick JE: Human acute myeloid
leukemia is organized as a hierarchy that originates from a
primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Singh SK, Clarke ID, Terasaki M, Bonn VE,
Hawkins C, Squire J and Dirks PB: Identification of a cancer stem
cell in human brain tumors. Cancer Res. 63:5821–5828.
2003.PubMed/NCBI
|
|
6
|
Miki J, Furusato B, Li H, Gu Y, Takahashi
H, Egawa S, Sesterhenn IA, McLeod DG, Srivastava S and Rhim JS:
Identification of putative stem cell markers, CD133 and CXCR4, in
hTERT-immortalized primary nonmalignant and malignant tumor-derived
human prostate epithelial cell lines and in prostate cancer
specimens. Cancer Res. 67:3153–3161. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fang D, Nguyen TK, Leishear K, Finko R,
Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE and Herlyn M: A
tumorigenic subpopulation with stem cell properties in melanomas.
Cancer Res. 65:9328–9337. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
Biffoni M, Todaro M, Peschle C and De Maria R: Identification and
expansion of human colon-cancer-initiating cells. Nature.
445:111–115. 2007. View Article : Google Scholar
|
|
9
|
O'Brien CA, Pollett A, Gallinger S and
Dick JE: A human colon cancer cell capable of initiating tumour
growth in immunodeficient mice. Nature. 445:106–110. 2007.
View Article : Google Scholar
|
|
10
|
Kim CF, Jackson EL, Woolfenden AE,
Lawrence S, Babar I, Vogel S, Crowley D, Bronson RT and Jacks T:
Identification of bronchioalveolar stem cells in normal lung and
lung cancer. Cell. 121:823–835. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bertolini G, Roz L, Perego P, Tortoreto M,
Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S,
et al: Highly tumorigenic lung cancer CD133+ cells
display stem-like features and are spared by cisplatin treatment.
Proc Natl Acad Sci USA. 106:16281–16286. 2009. View Article : Google Scholar
|
|
12
|
Vinogradov S and Wei X: Cancer stem cells
and drug resistance: The potential of nanomedicine. Nanomedicine.
7:597–615. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen K, Huang YH and Chen JL:
Understanding and targeting cancer stem cells: Therapeutic
implications and challenges. Acta Pharmacol Sin. 34:732–740. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Eyler CE and Rich JN: Survival of the
fittest: Cancer stem cells in therapeutic resistance and
angiogenesis. J Clin Oncol. 26:2839–2845. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shigdar S, Lin J, Li Y, Yang CJ, Wei M,
Zhus Y, Liu H and Duan W: Cancer stem cell targeting: The next
generation of cancer therapy and molecular imaging. Ther Deliv.
3:227–244. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sansone P and Bromberg J: Targeting the
interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol.
30:1005–1014. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sun Y, Moretti L, Giacalone NJ, Schleicher
S, Speirs CK, Carbone DP and Lu B: Inhibition of JAK2 signaling by
TG101209 enhances radiotherapy in lung cancer models. J Thorac
Oncol. 6:699–706. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Colomiere M, Ward AC, Riley C, Trenerry
MK, Cameron-Smith D, Findlay J, Ackland L and Ahmed N: Cross talk
of signals between EGFR and IL-6R through JAK2/STAT3 mediate
epithelial-mesenchymal transition in ovarian carcinomas. Br J
Cancer. 100:134–144. 2009. View Article : Google Scholar :
|
|
19
|
Behera R, Kumar V, Lohite K, Karnik S and
Kundu GC: Activation of JAK2/STAT3 signaling by osteopontin
promotes tumor growth in human breast cancer cells. Carcinogenesis.
31:192–200. 2010. View Article : Google Scholar
|
|
20
|
Zhao M, Gao FH, Wang JY, Liu F, Yuan HH,
Zhang WY and Jiang B: JAK2/STAT3 signaling pathway activation
mediates tumor angiogenesis by upregulation of VEGF and bFGF in
non-small-cell lung cancer. Lung Cancer. 73:366–374. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tan DS, Agarwal R and Kaye SB: Mechanisms
of transcoelomic metastasis in ovarian cancer. Lancet Oncol.
7:925–934. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Abubaker K, Luwor RB, Zhu H, McNally O,
Quinn MA, Burns CJ, Thompson EW, Findlay JK and Ahmed N: Inhibition
of the JAK2/STAT3 pathway in ovarian cancer results in the loss of
cancer stem cell-like characteristics and a reduced tumor burden.
BMC Cancer. 14:3172014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hsu HS, Lin JH, Hsu TW, Su K, Wang CW,
Yang KY, Chiou SH and Hung SC: Mesenchymal stem cells enhance lung
cancer initiation through activation of IL-6/JAK2/STAT3 pathway.
Lung Cancer. 75:167–177. 2012. View Article : Google Scholar
|
|
24
|
Marotta LL, Almendro V, Marusyk A,
Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ,
Choudhury SA, Maruyama R, et al: The JAK2/STAT3 signaling pathway
is required for growth of CD44+CD24− stem
cell-like breast cancer cells in human tumors. J Clin Invest.
121:2723–2735. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chauhan DP: Chemotherapeutic potential of
curcumin for colorectal cancer. Curr Pharm Des. 8:1695–1706. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Leu TH and Maa MC: The molecular
mechanisms for the anti-tumorigenic effect of curcumin. Curr Med
Chem Anticancer Agents. 2:357–370. 2002. View Article : Google Scholar
|
|
27
|
Karunagaran D, Rashmi R and Kumar TR:
Induction of apoptosis by curcumin and its implications for cancer
therapy. Curr Cancer Drug Targets. 5:117–129. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Duvoix A, Blasius R, Delhalle S,
Schnekenburger M, Morceau F, Henry E, Dicato M and Diederich M:
Chemopreventive and therapeutic effects of curcumin. Cancer Lett.
223:181–190. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fong D, Yeh A, Naftalovich R, Choi TH and
Chan MM: Curcumin inhibits the side population (SP) phenotype of
the rat C6 glioma cell line: Towards targeting of cancer stem cells
with phytochemicals. Cancer Lett. 293:65–72. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kakarala M, Brenner DE, Korkaya H, Cheng
C, Tazi K, Ginestier C, Liu S, Dontu G and Wicha MS: Targeting
breast stem cells with the cancer preventive compounds curcumin and
piperine. Breast Cancer Res Treat. 122:777–785. 2010. View Article : Google Scholar
|
|
31
|
Lim KJ, Bisht S, Bar EE, Maitra A and
Eberhart CG: A polymeric nanoparticle formulation of curcumin
inhibits growth, clonogenicity and stem-like fraction in malignant
brain tumors. Cancer Biol Ther. 11:464–473. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lin L, Liu Y, Li H, Li PK, Fuchs J,
Shibata H, Iwabuchi Y and Lin J: Targeting colon cancer stem cells
using a new curcumin analogue, GO-Y030. Br J Cancer. 105:212–220.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bao B, Ali S, Banerjee S, Wang Z, Logna F,
Azmi AS, Kong D, Ahmad A, Li Y, Padhye S, et al: Curcumin analogue
CDF inhibits pancreatic tumor growth by switching on suppressor
microRNAs and attenuating EZH2 expression. Cancer Res. 72:335–345.
2012. View Article : Google Scholar
|
|
34
|
Radhakrishna Pillai G, Srivastava AS,
Hassanein TI, Chauhan DP and Carrier E: Induction of apoptosis in
human lung cancer cells by curcumin. Cancer Lett. 208:163–170.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lin SS, Huang HP, Yang JS, Wu JY, Hsia TC,
Lin CC, Lin CW, Kuo CL, Gibson Wood W and Chung JG: DNA damage and
endoplasmic reticulum stress mediated curcumin-induced cell cycle
arrest and apoptosis in human lung carcinoma A-549 cells through
the activation caspases cascade- and mitochondrial-dependent
pathway. Cancer Lett. 272:77–90. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wu SH, Hang LW, Yang JS, Chen HY, Lin HY,
Chiang JH, Lu CC, Yang JL, Lai TY, Ko YC, et al: Curcumin induces
apoptosis in human non-small cell lung cancer NCI-H460 cells
through ER stress and caspase cascade- and mitochondria-dependent
pathways. Anticancer Res. 30:2125–2133. 2010.PubMed/NCBI
|
|
37
|
Gupta PB, Onder TT, Jiang G, Tao K,
Kuperwasser C, Weinberg RA and Lander ES: Identification of
selective inhibitors of cancer stem cells by high-throughput
screening. Cell. 138:645–659. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shao C, Sullivan JP, Girard L, Augustyn A,
Yenerall P, Rodriguez-Canales J, Liu H, Behrens C, Shay JW, Wistuba
II, et al: Essential role of aldehyde dehydrogenase 1A3 for the
maintenance of non-small cell lung cancer stem cells is associated
with the STAT3 pathway. Clin Cancer Res. 20:4154–4166. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Padilla F, Bhagirath N, Chen S, Chiao E,
Goldstein DM, Hermann JC, Hsu J, Kennedy-Smith JJ, Kuglstatter A,
Liao C, et al: Pyrrolopyrazines as selective spleen tyrosine kinase
inhibitors. J Med Chem. 56:1677–1692. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li RJ, Ying X, Zhang Y, Ju RJ, Wang XX,
Yao HJ, Men Y, Tian W, Yu Y, Zhang L, et al: All-trans retinoic
acid stealth liposomes prevent the relapse of breast cancer arising
from the cancer stem cells. J Control Release. 149:281–291. 2011.
View Article : Google Scholar
|
|
41
|
Grimshaw MJ, Cooper L, Papazisis K,
Coleman JA, Bohnenkamp HR, Chiapero-Stanke L, Taylor-Papadimitriou
J and Burchell JM: Mammosphere culture of metastatic breast cancer
cells enriches for tumorigenic breast cancer cells. Breast Cancer
Res. 10:R522008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ponti D, Costa A, Zaffaroni N, Pratesi G,
Petrangolini G, Coradini D, Pilotti S, Pierotti MA and Daidone MG:
Isolation and in vitro propagation of tumorigenic breast cancer
cells with stem/progenitor cell properties. Cancer Res.
65:5506–5511. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cioce M, Gherardi S, Viglietto G, Strano
S, Blandino G, Muti P and Ciliberto G: Mammosphere-forming cells
from breast cancer cell lines as a tool for the identification of
CSC-like- and early progenitor-targeting drugs. Cell Cycle.
9:2878–2887. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Park SY, Lee HE, Li H, Shipitsin M, Gelman
R and Polyak K: Heterogeneity for stem cell-related markers
according to tumor subtype and histologic stage in breast cancer.
Clin Cancer Res. 16:876–887. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Teng Y, Wang X, Wang Y and Ma D:
Wnt/beta-catenin signaling regulates cancer stem cells in lung
cancer A549 cells. Biochem Biophys Res Commun. 392:373–379. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yilmaz OH, Valdez R, Theisen BK, Guo W,
Ferguson DO, Wu H and Morrison SJ: Pten dependence distinguishes
haematopoietic stem cells from leukaemia-initiating cells. Nature.
441:475–482. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lin L, Fuchs J, Li C, Olson V, Bekaii-Saab
T and Lin J: STAT3 signaling pathway is necessary for cell survival
and tumorsphere forming capacity in
ALDH+/CD133+ stem cell-like human colon
cancer cells. Biochem Biophys Res Commun. 416:246–251. 2011.
View Article : Google Scholar : PubMed/NCBI
|
